Narcolepsy as an adverse event following immunization: Case definition and guidelines for data collection, analysis and presentation

Vaccine

Volumn 31, Issue 6, 2013, Pages 994-1007

  Poli, Francesca ^a   Overeem, Sebastiaan ^b   Lammers, Gert Jan ^c   Plazzi, Giuseppe ^a   Lecendreux, Michel ^d   Bassetti, Claudio L ^e   Dauvilliers, Yves ^f   Keene, Daniel ^g   Khatami, Ramin ^h   Li, Yulin ^i,j   Mayer, Geert ^k   Nohynek, Hanna ^l   Pahud, Barbara ^m   Paiva, Teresa ⁿ   Partinen, Markku ^o   Scammell, Thomas E ^p   Shimabukuro, Tom ^q   Sturkenboom, Miriam ^r   van Dinther, Kristy ^s   Wiznitzer, Max ^t   Bonhoeffer, Jan ^i,j   more..

^a IRCCS ISTITUTO DELLE SCIENZE NEUROLOGICHE DI BOLOGNA   (Italy)

^b RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^c LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

^d HÔPITAL ROBERT DEBRÉ   (France)

^e Neurologische Universitatsklinik Bern   (Switzerland)

^f MONTPELLIER UNIVERSITY HOSPITAL   (France)

^g HEALTH CANADA   (Canada)

^h Klinik Barmelweid   (Switzerland)

ⁱ UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^j Brighton Collaboration Foundation   (Switzerland)

^k Hephata Clinic for Neurology   (Germany)

^l NATIONAL PUBLIC HEALTH INSTITUTE   (Finland)

^m CHILDREN S MERCY HOSPITAL   (United States)

ⁿ CENC   (Portugal)

^o UNIVERSITY OF HELSINKI   (Finland)

^p BETH ISRAEL DEACONESS MEDICAL CENTER   (United States)

^q CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

^r ERASMUS MEDICAL CENTER   (Netherlands)

^s CSL Biotherapies   (Australia)

^t CASE WESTERN RESERVE UNIVERSITY   (United States)

more..

Author keywords

Autoimmunity; Cataplexy; Children ; Classification; H1N1; Hypocretin; Sleep

Indexed keywords

ANTIDEPRESSANT AGENT; CENTRAL STIMULANT AGENT; HLA DQB1 ANTIGEN; IMMUNOGLOBULIN; INFLUENZA VACCINE; OREXIN A; OXYBATE SODIUM;

2009 H1N1 INFLUENZA; ANTIGEN PRESENTATION; ARTICLE; BODY MASS; CATAPLEXY; CEREBROSPINAL FLUID ANALYSIS; DAYTIME SOMNOLENCE; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DRUG SAFETY; DYSTONIA; FOLLOW UP; HAPLOTYPE; HLA SYSTEM; HLA TYPING; HUMAN; IMMUNIZATION; IMMUNOCOMPETENT CELL; INFLUENZA A (H1N1); INFLUENZA VACCINATION; LUMBAR PUNCTURE; MEDICAL DECISION MAKING; MULTIPLE SLEEP LATENCY TEST; NARCOLEPSY; NEUROLOGIC EXAMINATION; PATHOPHYSIOLOGY; POSTMARKETING SURVEILLANCE; PRACTICE GUIDELINE; PREVALENCE; PRIORITY JOURNAL; REM SLEEP; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; TIC;

DATA COLLECTION; HUMANS; NARCOLEPSY; VACCINATION;

EID: 84872619045     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2012.12.014     Document Type: Article

References (173)

1. American Academy of Sleep Medicine International Classification of Sleep Disorders: diagnostic and coding manual 2005, American Academy of Sleep Medicine, Westchester, IL. 2nd ed.
2. Cave H. Narcolepsy. Arch Neurol Psychiatr 1931, 26:50-101.
3. Daniels L. Narcolepsy. Medicine (Baltimore) 1934, 13:1-122.
4. Sturzenegger C., Bassetti C.L. The clinical spectrum of narcolepsy with cataplexy: a reappraisal. J Sleep Res 2004, 13:395-406.
5. Plazzi G., Parmeggiani A., Mignot E., Lin L., Scano M.C., Posar A., et al. Narcolepsy-cataplexy associated with precocious puberty. Neurology 2006, 66:1577-1579.
6. Kok S.W., Overeem S., Visscher T.L., Lammers G.J., Seidell J.C., Pijl H., et al. Hypocretin deficiency in narcoleptic humans is associated with abdominal obesity. Obes Res 2003, 11:1147-1154.
7. Van Schie M.K., Thijs R.D., Fronczek R., Middelkoop H.A., Lammers G.J., Van Dijk J.G. Sustained attention to response task (SART) shows impaired vigilance in a spectrum of disorders of excessive daytime sleepiness. J Sleep Res 2012, 21:390-395.
8. Boulos M.I., Murray B.J. Current evaluation and management of excessive daytime sleepiness. Can J Neurol Sci 2010, 37:167-176.
9. Overeem S., van Nues S.J., van der Zande W.L., Donjacour C.E., van Mierlo P., Lammers G.J. The clinical features of cataplexy: a questionnaire study in narcolepsy patients with and without hypocretin-1 deficiency. Sleep Med 2011, 12:12-18.
10. Mendez M.F. Multiple sclerosis presenting as catatonia. Int J Psychiatry Med 1999, 29:435-441.
11. Fernandez J.M., Sadaba F., Villaverde F.J., Alvaro L.C., Cortina C. Cataplexy associated with midbrain lesion. Neurology 1995, 45:393-394.
12. D'Cruz O.F., Vaughn B.V., Gold S.H., Greenwood R.S. Symptomatic cataplexy in pontomedullary lesions. Neurology 1994, 44(11):2189-2191. [Erratum in: Neurology 1995;45:2123].
13. Stahl S.M., Layzer R.B., Aminoff M.J., Townsend J.J., Feldon S. Continuous cataplexy in a patient with a midbrain tumor: the limp man syndrome. Neurology 1980, 30:1115-1118.
14. Vanier M.T. Niemann-Pick disease type C. Orphanet J Rare Dis 2010, 5:16.
15. Crow Y.J., Zuberi S.M., McWilliam R., Tolmie J.L., Hollman A., Pohl K., et al. " Cataplexy" and muscle ultrasound abnormalities in Coffin-Lowry syndrome. J Med Genet 1998, 35:94-98.
16. Tyagi A., Harrington H. Cataplexy in association with Moebius syndrome. J Neurol 2003, 250:110-111.
17. Parkes J.D. Genetic factors in human sleep disorders with special reference to Norrie disease, Prader-Willi syndrome and Moebius syndrome. J Sleep Res 1999, 8:14-22.
18. Vossler D.G., Wyler A.R., Wilkus R.J., Gardner-Walker G., Vlcek B.W. Cataplexy and monoamine oxidase deficiency in Norrie disease. Neurology 1996, 46:1258-1261.
19. Nevsimalova S., Buskova J., Bruha R., Kemlink D., Sonka K., Vitek L., et al. Sleep disorders in Wilson's disease. Eur J Neurol 2011, 18:184-190.
20. Nishino S., Ripley B., Overeem S., Lammers G.J., Mignot E. Hypocretin (orexin) deficiency in human narcolepsy. Lancet 2000, 355:39-40.
21. Mignot E., Lammers G.J., Ripley B., Okun M., Nevsimalova S., Overeem S., et al. The role of cerebrospinal fluid hypocretin measurement in the diagnosis of narcolepsy and other hypersomnias. Arch Neurol 2002, 59:1553-1562.
22. Bourgin P., Zeitzer J.M., Mignot E. CSF hypocretin-1 assessment in sleep and neurological disorders. Lancet Neurol 2008, 7:649-662.
23. Oka Y., Inoue Y., Kanbayashi T., Kuroda K., Miyamoto M., Miyamoto T., et al. Narcolepsy without cataplexy: 2 subtypes based on CSF hypocretin-1/orexin-A findings. Sleep 2006, 29:1439-1443.
24. Andlauer O., Moore I.V.H., Hong S.C., Dauvilliers D., Kanbayashi T., Nishino S., et al. Predictors of hypocretin (orexin) deficiency in narcolepsy without cataplexy. Sleep 2012, 35:1247F-1255F.
25. Baumann C.R., Stocker R., Imhof H.G., Trentz O., Hersberger M., Mignot E., et al. Hypocretin-1 (orexin A) deficiency in acute traumatic brain injury. Neurology 2005, 65:147-149.
26. Rejdak K., Petzold A., Lin L., Smith M., Kitchen N., Thompson E.J. Decreased CSF hypocretin-1 (orexin-A) after acute haemorrhagic brain injury. J Neurol Neurosurg Psychiatry 2005, 76:597-598.
27. Ripley B., Overeem S., Fujiki N., Nevsimalova S., Uchino M., Yesavage J., et al. CSF hypocretin/orexin levels in narcolepsy and other neurological conditions. Neurology 2001, 57:2253-2258.
28. Scammell T.E., Nishino S., Mignot E., Saper C.B. Narcolepsy and low CSF orexin (hypocretin) concentration after a diencephalic stroke. Neurology 2001, 56:1751-1753.
29. Rejdak K., Papuc E., Grieb P., Stelmasiak Z. Decreased cerebrospinal fluid hypocretin-1 (orexin A) in patients after repetitive generalized tonic-clonic seizures. Epilepsia 2009, 50:1641-1644.
30. Kubota H., Kanbayashi T., Tanabe Y., Takanashi J., Kohno Y. A case of acute disseminated encephalomyelitis presenting hypersomnia with decreased hypocretin level in cerebrospinal fluid. J Child Neurol 2002, 17:537-539.
31. Nevsimalova S., Vankova J., Stepanova I., Seemanova E., Mignot E., Nishino S. Hypocretin deficiency in Prader-Willi syndrome. Eur J Neurol 2005, 12:70-72.
32. Vankova J., Stepanova I., Jech R., Elleder M., Ling L., Mignot E., et al. Sleep disturbances and hypocretin deficiency in Niemann-Pick disease type C. Sleep 2003, 26:427-430.
33. Drouot X., Moutereau S., Nguyen J.P., Lefaucheur J.P., Creange A., Remy P., et al. Low levels of ventricular CSF orexin/hypocretin in advanced PD. Neurology 2003, 61:540-543.
34. Fronczek R., Overeem S., Lee S.Y., Hegeman I.M., van Pelt J., van Duinen S.G., et al. Hypocretin (orexin) loss in Parkinson's disease. Brain 2007, 130:1577-1585.
35. Oka Y., Kanbayashi T., Mezaki T., Iseki K., Matsubayashi J., Murakami G., et al. Low CSF hypocretin-1/orexin-A associated with hypersomnia secondary to hypothalamic lesion in a case of multiple sclerosis. J Neurol 2004, 251:885-886.
36. Winkelmann J., Lin L., Schormair B., Kornum B.R., Faraco J., Plazzi G., et al. Mutations in DNMT1 cause autosomal dominant cerebellar ataxia, deafness and narcolepsy. Hum Mol Genet 2012, 21:2205-2210.
37. Nishino S., Ripley B., Overeem S., Nevsimalova S., Lammers G.J., Vankova J., et al. Low cerebrospinal fluid hypocretin (Orexin) and altered energy homeostasis in human narcolepsy. Ann Neurol 2001, 50:381-388.
38. Aldrich M.S., Chervin R.D., Malow B.A. Value of the multiple sleep latency test (MSLT) for the diagnosis of narcolepsy. Sleep 1997, 20:620-629.
39. Johns M.W. Sensitivity and specificity of the multiple sleep latency test (MSLT), the maintenance of wakefulness test and the epworth sleepiness scale: failure of the MSLT as a gold standard. J Sleep Res 2000, 9:5-11.
40. Longstreth W.T., Koepsell T.D., Ton T.G., Hendrickson A.F., van Belle G. The epidemiology of narcolepsy. Sleep 2007, 30:13-26.
41. Silber M.H., Krahn L.E., Olson E.J., Pankratz V.S. The epidemiology of narcolepsy in Olmsted County, Minnesota: a population-based study. Sleep 2002, 25:197-202.
42. Yoss R.E., Daly D.D. Narcolepsy in children. Pediatrics 1960, 25:1025-1033.
43. Chakravorty S.S., Rye D.B. Narcolepsy in the older adult: epidemiology, diagnosis and management. Drugs Aging 2003, 20:361-376.
44. Dauvilliers Y., Montplaisir J., Molinari N., Carlander B., Ondze B., Besset A., et al. Age at onset of narcolepsy in two large populations of patients in France and Quebec. Neurology 2001, 57:2029-2033.
45. Passouant P., Billiard M. The evolution of narcolepsy with age. Narcolepsy 1976, 179-196. Spectrum, New York. C. Guilleminault, W.C. Dement, P. Passouant (Eds.).
46. Overeem S., Mignot E., van Dijk J.G., Lammers G.J. Narcolepsy: clinical features, new pathophysiologic insights, and future perspectives. J Clin Neurophysiol 2001, 18:78-105.
47. Mayer G., Kesper K., Ploch T., Peter H., Peter J. The implications of gender and age at onset of first symptoms in narcoleptic patients in Germany-results from retrospective evaluation of hospital records. Somnologie 2002, 6:13-18.
48. Morrish E., King M.A., Smith I.E., Shneerson J.M. Factors associated with a delay in the diagnosis of narcolepsy. Sleep Med 2004, 5:37-41.
49. Guilleminault C., Pelayo R. Narcolepsy in prepubertal children. Ann Neurol 1998, 43:135-142.
50. Serra L., Montagna P., Mignot E., Lugaresi E., Plazzi G. Cataplexy features in childhood narcolepsy. Mov Disord 2008, 23:858-865.
51. Plazzi G., Pizza F., Palaia V., Franceschini C., Poli F., Moghadam K.K., et al. Complex movement disorders at disease onset in childhood narcolepsy with cataplexy. Brain 2011, 134:3480-3492.
52. Thannickal T.C., Moore R.Y., Nienhuis R., Ramanathan L., Gulyani S., Aldrich M., et al. Reduced number of hypocretin neurons in human narcolepsy. Neuron 2000, 27:469-474.
53. Peyron C., Faraco J., Rogers W., Ripley B., Overeem S., Charnay Y., et al. A mutation in a case of early onset narcolepsy and a generalized absence of hypocretin peptides in human narcoleptic brains. Nat Med 2000, 6:991-997.
54. Crocker A., Espana R.A., Papadopoulou M., Saper C.B., Faraco J., Sakurai T., et al. Concomitant loss of dynorphin, NARP, and orexin in narcolepsy. Neurology 2005, 65:1184-1188.
55. Mignot E., Hayduk R., Black J., Grumet F.C., Guilleminault C. HLA DQB1*0602 is associated with cataplexy in 509 narcoleptic patients. Sleep 1997, 20:1012-1020.
56. Black J.L. Narcolepsy: a review of evidence for autoimmune diathesis. Int Rev Psychiatry 2005, 16:461-469.
57. Tanaka S., Honda Y., Inoue Y., Honda M. Detection of autoantibodies against hypocretin, hcrtrl, and hcrtr2 in narcolepsy: anti-Hcrt system antibody in narcolepsy. Sleep 2006, 29:633-638.
58. Scammell T.E. The frustrating and mostly fruitless search for an autoimmune cause of narcolepsy. Sleep 2006, 29:601-602.
59. Martinez-Rodriguez J.E., Sabater L., Graus F., Iranzo A., Santamaria J. Evaluation of hypothalamic-specific autoimmunity in patients with narcolepsy. Sleep 2007, 30:27-28.
60. Overeem S., Black J.L., Lammers G.J. Narcolepsy: immunological aspects. Sleep Med Rev 2008, 12:95-107.
61. Hallmayer J., Faraco J., Lin L., Hesselson S., Winkelmann J., Kawashima M., et al. Narcolepsy is strongly associated with the T-cell receptor alpha locus. Nat Genet 2009, 41:708-711.
62. Kornum B.R., Kawashima M., Faraco J., Lin L., Rico T.J., Hesselson S., et al. Common variants in P2RY11 are associated with narcolepsy. Nat Genet 2011, 43:66-71.
63. Aran A., Lin L., Nevsimalova S., Plazzi G., Hong S.C., Weiner K., et al. Elevated anti-streptococcal antibodies in patients with recent narcolepsy onset. Sleep 2009, 32:979-983.
64. Cvetkovic-Lopes V., Bayer L., Dorsaz S., Maret S., Pradervand S., Dauvilliers Y., et al. Elevated Tribbles homolog 2-specific antibody levels in narcolepsy patients. J Clin Invest 2010, 120:713-719.
65. Aldrich M.S. The clinical spectrum of narcolepsy and idiopathic hypersomnia. Neurology 1996, 46:393-401.
66. Billiard M. Narcolepsy. Clinical features and aetiology. Ann Clin Res 1985, 17:220-226.
67. Honda Y. Clinical features of narcolepsy: Japanese experiences. HLA in narcolepsy 1988, 24-57. Springer-Verlag, Berlin. T. Honda, T. Juji (Eds.).
68. Guilleminault C., Abad V. Narcolepsy. Sleep disorders medicine. Basic science, technical considerations, and clinical aspects 2009, 377-396. Elsevier Inc., Philadelphia, PA. S. Chokroverty (Ed.).
69. Dauvilliers Y., Baumann C.R., Carlander B., Bischof M., Blatter T., Lecendreux M., et al. CSF hypocretin-1 levels in narcolepsy, Kleine-Levin syndrome, and other hypersomnias and neurological conditions. J Neurol Neurosurg Psychiatry 2003, 74:1667-1673.
70. Baumann C., Bassetti Cl. Hypocretin an narcolepsy. Lancet Neurol 2003, 10:673-682.
71. Thannickal T.C., Nienhuis R., Siegel J.M. Localized loss of hypocretin (orexin) cells in narcolepsy without cataplexy. Sleep 2009, 32:993-998.
72. Marti I., Valko P.O., Khatami R., Bassetti C.L., Baumann C.R. Multiple sleep latency measures in narcolepsy and behaviourally induced insufficient sleep syndrome. Sleep Med 2009, 10:1146-1150.
73. Mignot E., Lin L., Finn L., Lopes C., Pluff K., Sundstrom M.L., et al. Correlates of sleep-onset REM periods during the Multiple Sleep Latency Test in community adults. Brain 2006, 129:1609-1623.
74. Sleep Disorders Classification Committee (Roffwarg HP, Chairman). Association of Sleep Disorders Centers. Diagnostic classification of sleep and arousal disorders, 1st ed., vol. 2. Sleep; 1979. p. 1-137.
75. Diagnostic Classification Steering Committee (Thorpy MJ, chairman). International Classification of Sleep Disorders diagnostic and coding manual. Rochester, MN: American Sleep Disorders Association; 1990.
76. Eurosurveillance Editorial Team European Medicines Agency updates on the review of Pandemrix and reports of narcolepsy. Euro Surveill 2010, 15. pii:19670. Available at: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19670.
77. Medical Products Agency (MPA). Occurrence of narcolepsy with cataplexy among children and adolescents in relation to the H1N1 pandemic and Pandemrix vaccinations-results of a case inventory study by the MPA in Sweden during 2009-2010. Available at: ; 2011. http://www.lakemedelsverket.se/upload/nyheter/2011/Fallinventeringsrapport_pandermrix_110630.pdf.
78. Eurosurveillance Editorial Team Swedish Medical Products Agency publishes report from a case inventory study on Pandemrix vaccination and development of narcolepsy with cataplexy. Euro Surveill 2011, 16. pii:19904. Available at: http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=19904.
79. National Institute for Health and Welfare. National Institute for Health and Welfare recommends discontinuation of Pandemrix vaccinations. Available at: http://www.thl.fi/doc/en/22930.
80. Dauvilliers Y., Montplaisir J., Cochen V., Desautels A., Einen M., Lin L., et al. Post-H1N1 narcolepsy-cataplexy. Sleep 2010, 33:1428-1430.
81. Bardage C., Persson I., Ortqvist A., Bergman U., Ludvigsson J.F., Granath F. Neurological and autoimmune disorders after vaccination against pandemic influenza A (H1N1) with a monovalent adjuvanted vaccine: population based cohort study in Stockholm,Sweden. BMJ 2011, 343:d5956.
82. Haba-Rubio J., Rossetti A.O., Tafti M., Heinzer R. Narcolepsy with cataplexy associated with H1N1 vaccination. Rev Neurol 2011, 167:563-566.
83. Han F., Lin L., Warby S.C., Faraco J., Li J., Dong S.X., et al. Narcolepsy onset is seasonal and increased following the 2009 H1N1 pandemic in China. Ann Neurol 2011, 70:410-417.
84. Kallweit U., Hidlgo H., Engel A., et al. Post H1N1 vaccination narcolepsy-cataplexy with decreased CSF beta-amyloid. Sleep Med 2012, 13:323.
85. Kohl K.S., Walop W., Gidudu J., Ball L., Halperin S., Hammer S.J., et al. Induration at or near injection site: case definition and guidelines for collection, analysis, and presentation of immunization safety data. Vaccine 2007, 25:5839-5857.
86. Schenck C.H., Bassetti C.L., Arnulf I., Mignot E. English translations of the first clinical reports on narcolepsy and cataplexy by Westphal and Gelineau in the late 19th century, with commentary. J Clin Sleep Med 2007, 3:301-311.
87. Adie W. Idiopathic narcolepsy: a disease sui generis: with remarks on the mechanism of sleep. Brain 1926, 49:257-306.
88. Loewenfeld L. Ueber Narkolepsie. Muenchener Medizische Wochenschrift 1902, 49:1041-1045.
89. Rechtschaffen A., Wolpert E.A., Dement W.C., Mitchell S.A., Fisher C. Nocturnal sleep of narcoleptics. Electroencephalogr Clin Neurophysiol 1966, 15:599-609.
90. Guillemianult C., Dement W.C. Pathologies of excessive sleep. Advances in sleep research 1974, vol. 1:345-390. Spectrum, New York.
91. Richardson G.S., Carskadon M.A., Flagg W., Van den Hoed J., Dement W.C., Mitler M.M. Excessive daytime sleepiness in man: multiple sleep latency measurement in narcoleptic and control subjects. Electroencephalogr Clin Neurophysiol 1978, 45:621-627.
92. Mitler M.M., Van den Hoed J., Carskadon M.A., Richardson G., Park R., Guilleminault C., et al. REM sleep episodes during the Multple Sleep Latency Test in narcoleptic patients. Electroencephalogr Clin Neurophysiol 1979, 46:479-481.
93. Amira S.A., Johnson T.S., Logowitz N.B. Diagnosis of narcolepsy using the multiple sleep latency test: analysis of current laboratory criteria. Sleep 1985, 8:325-331.
94. Silber M.H. The multiple sleep latency test in the diagnosis of sleep disorders. S Afr Med J 1990, 77:82-84.
95. Lammers G.J., van Dijk J.G. The Multiple Sleep Latency Test: a paradoxical test?. Clin Neurol Neurosurg 1992, 94:S108-S110.
96. American Academy of Neurology Assessment: techniques associated with the diagnosis and management of sleep disorders. Report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 1992, 42:269-275.
97. Moscovitch A., Partinen M., Guilleminault C. The positive diagnosis of narcolepsy and narcolepsy's borderland. Neurology 1993, 43:55-60.
98. Chervin R.D., Aldrich M.S., Pickett R., Guilleminault C. Comparison of the results of the Epworth Sleepiness Scale and the Multiple Sleep Latency Test. J Psychosom Res 1997, 42:145-155.
99. Dauvilliers Y., Gosselin A., Paquet J., Touchon J., Billiard M., Montplaisir J. Effect of age on MSLT results in patients with narcolepsy-cataplexy. Neurology 2004, 62:46-50.
100. Arand D., Bonnet M., Hurwitz T., Mitler M., Rosa R., Sangal R.B. The clinical use of the MSLT and MWT. Sleep 2005, 28:123-144.
101. Littner M.R., Kushida C., Wise M., Davila D.G., Morgenthaler T., Lee-Chiong T., et al. Practice parameters for clinical use of the multiple sleep latency test and the maintenance of wakefulness test. Sleep 2005, 28:113-121.
102. Hong S.C., Lin L., Jeong J.H., Shin Y.K., Han J.H., Lee J.H., et al. A study of the diagnostic utility of HLA typing, CSF hypocretin-1 measurements, and MSLT testing for the diagnosis of narcolepsy in 163 Korean patients with unexplained excessive daytime sleepiness. Sleep 2006, 29:1429-1438.
103. Siegel J.M. The narcoleptic borderland. Sleep Med 2003, 4:3-4.
104. Bassetti C., Gugger M., Bischof M., Mathis J., Sturzenegger C., Werth E., et al. The narcoleptic borderland: a multimodal diagnostic approach including cerebrospinal fluid levels of hypocretin-1 (orexin A). Sleep Med 2003, 4:7-12.
105. Krahn L.E., Pankratz V.S., Oliver L., Boeve B.F., Silber M.H. Hypocretin (orexin) levels in cerebrospinal fluid of patients with narcolepsy: relationship to cataplexy and HLA DQB1* 0602 status. Sleep 2002, 25:733-736.
106. Jacome D.E., Risko M. Pseudocataplexy: gelastic-atonic seizures. Neurology 1984, 34:1381-1383.
107. Krahn L.E., Hansen M.R., Shepard J.W. Pseudocataplexy. Psychosomatics 2001, 42:356-358.
108. Simon D.K., Nishino S., Scammell T.E. Mistaken diagnosis of psychogenic gait disorder in a man with status cataplecticus (" limp man syndrome" ). Mov Disord 2004, 19:838-840.
109. Krahn L.E. Reevaluating spells initially identified as cataplexy. Sleep Med 2005, 6:537-542.
110. Calabro R.S., Savica R., Lagana A., Magaudda A., Imbesi D., Gallitto G., et al. Status cataplecticus misdiagnosed as recurrent syncope. Neurol Sci 2007, 28:336-338.
111. Plazzi G., Khatami R., Serra L., Pizza F., Bassetti C.L. Pseudocataplexy in narcolepsy with cataplexy. Sleep Med 2010, 11:591-594.
112. Shankar R., Jalihal V., Walker M., Zeman A. Pseudocataplexy and transient functional paralysis: a spectrum of psychogenic motor disorder. J Neuropsychiatry Clin Neurosci 2010, 22:445-450.
113. Guilleminault C., Wilson R.A., Dement W.C. A study on cataplexy. Arch Neurol 1974, 31:255-261.
114. Rubboli G., d'Orsi G., Zaniboni A., Gardella E., Zamagni M., Rizzi R., et al. A video-polygraphic analysis of the cataplectic attack. Clin Neurophysiol 2000, 111:S120-S128.
115. Lammers G.J., Overeem S., Tijssen M.A., van Dijk J.G. Effects of startle and laughter in cataplectic subjects: a neurophysiological study between attacks. Clin Neurophysiol 2000, 11:1276-1281.
116. Augustine K., Cameron B., Camp J., Krahn L., Robb R. An immersive simulation system for provoking and analyzing cataplexy. Stud Health Technol Inform 2002, 85:31-37.
117. Okun M.L., Lin L., Pelin Z., Hong S., Mignot E. Clinical aspects of narcolepsy-cataplexy across ethnic groups. Sleep 2002, 25:27-35.
118. Dhondt K., Verhelst H., Pevernagie D., Slap F., Van Coster R. Childhood narcolepsy with partial facial cataplexy: a diagnostic dilemma. Sleep Med 2009, 10:797-798.
119. Vetrugno R., D'Angelo R., Moghadam K.K., Vandi S., Franceschini C., Mignot E., et al. Behavioural and neurophysiological correlates of human cataplexy: a video-polygraphic study. Clin Neurophysiol 2010, 121:153-162.
120. Silber M.H., Krahn L.E., Olson E.J. Diagnosing narcolepsy: validity and reliability of new diagnostic criteria. Sleep Med 2002, 3:109-113.
121. Morrison I., Buskova J., Nevsimalova S., Douglas N.J., Riha R.L. Diagnosing narcolepsy with cataplexy on history alone: challenging the International Classification of Sleep Disorders (ICSD-2) criteria. Eur J Neurol 2011, 18:1017-1020.
122. Knudsen S., Jennum P.J., Alving J., Sheikh S.P., Gammeltoft S. Validation of the ICSD-2 criteria for CSF hypocretin-1 measurements in the diagnosis of narcolepsy in the Danish population. Sleep 2010, 33:169-176.
123. Heier M.S., Evsiukova T., Vilming S., Gjerstad M.D., Schrader H., Gautvik K. CSF hypocretin-1 levels and clinical profiles in narcolepsy and idiopathic CNS hypersomnia in Norway. Sleep 2007, 30:969-973.
124. Arii J., Kanbayashi T., Tanabe Y., Sawaishi Y., Kimura S., Watanabe A., et al. CSF hypocretin-1 (orexin-A) levels in childhood narcolepsy and neurologic disorders. Neurology 2004, 63:2440-2442.
125. Kunimoto M. The level of hypocretin 1 (orexin A) in cerebrospinal fluid and the diagnosis of narcolepsy and other somnolent disorders. Intern Med 2003, 42:634-635.
126. Overeem S., Scammell T.E., Lammers G.J. Hypocretin/orexin and sleep: implications for the pathophysiology and diagnosis of narcolepsy. Curr Opin Neurol 2002, 15:739-745.
127. Kanbayashi T., Yano T., Ishiguro H., Kawanishi K., Chiba S., Aizawa R., et al. Hypocretin-1 (orexin-A) levels in human lumbar CSF in different age groups: infants to elderly persons. Sleep 2002, 25:337-339.
128. Lin L., Bassetti C.L., Lammers G.J., Nishino S., Silber M.H., Kanbayashi T., et al. Guidelines for the appropriate use of CSF measurements to diagnose narcolepsy. Narcolepsy and hypersomnia 2006, 663-670. Informa Healthcare, New York. 1st ed. C.L. Bassetti, M. Billiard, E. Mignot (Eds.).
129. Nicoll D., Detmer W.M. Diagnostic testing and medical decision making. Current medical diagnosis and treatment 1999, 550-560. Appleton and Lange, Stanford. L.M. Tierney, S.J. McPhee, M.A. Papadakis (Eds.).
130. Dauvilliers Y., Abril B., Mas E., Michel F., Tafti M. Normalization of hypocretin-1 in narcolepsy after intravenous immunoglobulin treatment. Neurology 2009, 73:1333-1334.
131. Anic-Labat S., Guilleminault C., Kraemer H.C., Meehan J., Arrigoni J., Mignot E. Validation of a cataplexy questionnaire in 983 sleep-disorders patients. Sleep 1999, 22:77-87.
132. Hublin C., Kaprio J., Partinen M., Koskenvuo M., Heikkila K., Koskimies S., Guilleminault C. The prevalence of narcolepsy: an epidemiological study of the Finnish Twin Cohort. Ann Neurol 1994, 35:709-716.
133. Charles S.T., Carstensen L.L. Social and emotional aging. Annu Rev Psychol 2010, 61:383-409.
134. Aran A., Einen M., Lin L., Plazzi G., Nishino S., Mignot E. Clinical and therapeutic aspects of childhood narcolepsy-cataplexy: a retrospective study of 51 children. Sleep 2010, 33:1457-1464.
135. Nevsimalova S. Narcolepsy in childhood. Sleep Med Rev 2009, 13:169-180.
136. Honda Y., Asaka A., Tanimura M., Furusho T. A genetic study of narcolepsy and excessive daytime sleepiness in 308 families with a narcolepsy or hypersomnia proband. Sleep/wake disorders: natural history, epidemiology and long term evolution 1983, 187-199. Raven, New York. C. Guilleminault, E. Lugaresi (Eds.).
137. Broughton R., Dunham W., Newman J., Lutley K., Duschesne P., Rivers M. Ambulatory 24h sleep-wake monitoring in narcolepsy-cataplexy compared to matched controls. Electroencephalogr Clin Neurophysiol 1988, 70:473-481.
138. Plazzi G., Serra L., Ferri R. Nocturnal aspects of narcolepsy with cataplexy. Sleep Med Rev 2008, 12:109-128.
139. Montplaisir J., Billiard M., Takahashi S., Bell I.R., Guilleminault C., Dement W.C. Twenty-four-hour recording in REM-narcoleptics with special reference to nocturnal sleep disruption. Biol Psychiatry 1978, 13:73-89.
140. Carrot B., Lecendreux M. Evaluation of excessive daytime sleepiness in child and adolescent psychopathology. Arch Pediatr 2011, 18:891-901.
141. Mazza M., Faia V., Paciello N., Della Marca G., Mazza S. Sleep disorders in childhood: a review. Clin Ter 2002, 153:189-193.
142. Kotagal S. Sleep disorders in childhood. Neurol Clin 2003, 21:961-981.
143. Kotagal S., Pianosi P. Sleep disorders in children and adolescents. BMJ 2006, 332(7545):828-832.
144. Meltzer L.J., Mindell J.A. Sleep and sleep disorders in children and adolescents. Psychiatr Clin North Am 2006, 29:1059-1076.
145. Kothare S.V., Kaleyias J. Narcolepsy and other hypersomnias in children. Curr Opin Pediatr 2008, 20:666-675.
146. Kothare S.V., Kaleyias J. The clinical and laboratory assessment of the sleepy child. Semin Pediatr Neurol 2008, 15:61-69.
147. Lecendreux M., Dauvilliers Y., Arnulf I., Franco P. Narcolepsy with cataplexy in the child: clinical evaluation and therapeutical management. Rev Neurol 2008, 164:646-657.
148. Vendrame M., Havaligi N., Matadeen-Ali C., Adams R., Kothare S.V. Narcolepsy in children: a single-center clinical experience. Pediatr Neurol 2008, 38:314-320.
149. Sullivan S.S. Narcolepsy in adolescents. Adolesc Med State Art Rev 2010, 21:542-555. x-xi.
150. Peraita-Adrados R., Garcia-Penas J.J., Ruiz-Falco L., Gutierrez-Solana L., Lopez-Esteban P., Vicario J.L., et al. Clinical, polysomnographic and laboratory characteristics of narcolepsy-cataplexy in a sample of children and adolescents. Sleep Med 2011, 12:24-27.
151. Guilleminault C., Pelayo R. Narcolepsy in children: a practical guide to its diagnosis, treatment and follow-up. Paediatr Drugs 2000, 2:1-9.
152. Dorris L., Zuberi S.M., Scott N., Moffat C., McArthur I. Psychosocial and intellectual functioning in childhood narcolepsy. Dev Neurorehabil 2008, 11:187-194.
153. Nohynek H., Jokinen J., Partinen M., Vaarala O., Kirjavainen T., Sundman J., et al. AS03 adjuvanted AH1N1 vaccine associated with an abrupt increase in the incidence of childhood narcolepsy in Finland. PLoS ONE 2012, 7:e33536.
154. Partinen M., Saarenpaa-Heikkila O., Ilveskoski I., Hublin C., Linna M., Olsen P., et al. Increased incidence and clinical picture of childhood narcolepsy following the 2009 H1N1 pandemic vaccination campaign in Finland. PLoS ONE 2012, 7:e33723.
155. Carskadon M.A., Dement W.C., Mitler M.M., Roth T., Westbrook P.R., Keenan S. Guidelines for the multiple sleep latency test (MSLT): a standard measure of sleepiness. Sleep 1986, 9:519-524.
156. Bishop C., Rosenthal L., Helmus T., Roehrs T., Roth T. The frequency of multiple sleep onset REM periods among subjects with no excessive daytime sleepiness. Sleep 1996, 19:727-730.
157. Andlauer O., Moore H.E., Han F., Hong S., Plazzi G., Haffen E., et al. Short REM latency as a screening tool for narcolepsy. Sleep 2012, 35:A269.
158. Wise M.S. Childhood narcolepsy. Neurology 1998, 50:S37-S42.
159. Carskadon M.A., Harvey K., Duke P., Anders T.F., Litt I.F., Dement W.C. Pubertal changes in daytime sleepiness. Sleep 1980, 2:453-460.
160. Geisler P., Tracik F., Cronlein T., Fulda S., Wichniak A., Popp R., et al. The influence of age and sex on sleep latency in the MSLT-30-a normative study. Sleep 2006, 29:687-692.
161. Dauvilliers Y., Arnulf I., Mignot E. Narcolepsy with cataplexy. Lancet 2007, 369:499-511.
162. Kotagal S., Hartse K.M., Walsh J.K. Characteristics of narcolepsy in preteenaged children. Pediatrics 1990, 85:205-209.
163. Peterson P.C., Husain A.M. Pediatric narcolepsy. Brain Dev 2008, 30:609-623.
164. Mignot E. Genetics of narcolepsy and other sleep disorders. Am J Hum Genet 1997, 60:1289-1302.
165. Hor H., Kutalik Z., Dauvilliers Y., Valsesia A., Lammers G.J., Donjacour C.E., et al. Genome-wide association study identifies new HLA class II haplotypes strongly protective against narcolepsy. Nat Genet 2010, 42:786-789.
166. Mignot E., Lin L., Rogers W., Honda Y., Qiu X., Lin X., et al. Complex HLA-DR and -DQ interactions confer risk of narcolepsy-cataplexy in three ethnic groups. Am J Hum Genet 2001, 68:686-699.
167. International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH). Guidelines for Clinical Safety Assessment (E2a-e). Available at: [accessed 27.04.12]. http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E2A/Step4/E2A_Guideline.pdf.
168. Council for International Organizations of Medical Sciences (CIOMS). Reporting form for International Reporting of Adverse Drug Reactions. Available at: [accessed 27.04.12]. http://www.cioms.ch/form/frame_form.htm.
169. Moher D., Schulz K.F., Altman D. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomized trials. JAMA 2001, 285:1987-1991.
170. Moher D., Cook D.J., Eastwood S., Olkin I., Rennie D., Stroup D.F. Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement. Quality of Reporting of Meta-analyses. Lancet 1999, 354:1896-1900.
171. Stroup D.F., Berlin J.A., Morton S.C., Olkin I., Williamson G.D., Rennie D., et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group. JAMA 2000, 283:2008-2012.
172. Des Jarlais D.C., Lyles C., Crepaz N. Improving the reporting quality of nonrandomized evaluations of behavioral and public health interventions: the TREND statement. Am J Public Health 2004, 94:361-366.
173. Vandenbroucke J.P., von Elm E., Altman D.G., Gotzsche P.C., Mulrow C.D., Pocock S.J., et al. Strengthening the Reporting of Observational Studies in Epidemiology (STROBE): explanation and elaboration. PLoS Med 2007, 4:e297.